Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...
The atherosclerotic cardiovascular disease market in the 7MM is expected to show positive growth during the forecast period (2025–2034), mainly attributed to the launch of upcoming therapies such as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback